Myungin Pharm명인제약
317450 · KOSPI · ₩317450 · 명인제약
- Market cap
- ₩587B
- Enterprise value
- ₩139B
- P/E
- 7.2×
- P/B
- 0.7×
- Dividend yield
- 3.7%
- ROE
- 10.0%
- Net margin
- 28.3%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−56.6% from the high
₩39,100Today: ₩39,850 – ₩40,950₩92,600
Returns
- 1W−3.4%
- 1M−4.3%
- 3M−1.5%
- 6M−28.5%
- YTD−41.7%
- 1Y−55.8%
- Volume today
- 6,826
- 0.6× the 20-day average
- Traded today
- ₩274M
- Listed shares
- 14,600,000
- EPS (12 months)
- ₩5,578
- Earnings yield 13.9%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 40 of 100 (50 is a normal day for this stock).
- MomentumFlat-4.4% over the last month; the price is below its 20-day average.
Signals describe activity, not recommendations. Not financial advice.
Myungin Pharm stock overview
Myungin Pharm (명인제약, KRX: 317450) is listed on KOSPI, in the Biotech & Pharma sector. The company develops, manufactures and sells prescription drugs focused on the central nervous system, including treatments for stroke, Parkinson's disease, schizophrenia and depression, and also sells over-the-counter products such as a gum-care brand and a constipation remedy. Its shares closed at ₩40,200 on Oct 27, 2026, up 0.75% on the day, giving it a market value of ₩587B.
Key facts
- Market cap
- ₩587B
- Sector
- Biotech & Pharma
- Latest price change
- +0.75%
- As of
- Oct 27, 2026
- Main business
- The company develops, manufactures and sells prescription drugs focused on the central nervous system, including treatments for stroke, Parkinson's disease, schizophrenia and depression, and also sells over-the-counter products such as a gum-care brand and a constipation remedy.
Quick answers about Myungin Pharm
- What does Myungin Pharm do?
- The company develops, manufactures and sells prescription drugs focused on the central nervous system, including treatments for stroke, Parkinson's disease, schizophrenia and depression, and also sells over-the-counter products such as a gum-care brand and a constipation remedy. It handles production from raw material synthesis through finished drug manufacturing, supplies pharmaceutical products primarily in South Korea, and has formed partnerships with global pharmaceutical companies to pursue markets in the United States, Europe, China and Japan.
- What is the market cap of Myungin Pharm?
- The market capitalisation of Myungin Pharm was ₩587B at the close on Oct 27, 2026.
- Who are the largest shareholders of Myungin Pharm?
- According to the latest official filings, the largest reported holders are Lee Haeng-myeong (73.47%, as of May 8, 2026); Lee Seon-young (12.05%, as of May 8, 2026); Lee Ja-young (10.27%, as of May 8, 2026).
- When is the next earnings report from Myungin Pharm?
- Korean companies rarely announce results dates in advance. Based on when Myungin Pharm filed the same report in past years, its next preliminary results is expected around Oct 31, 2026.
- Does the National Pension Service own Myungin Pharm?
- Yes. The National Pension Service held 0.68% of Myungin Pharm shares as of Dec 31, 2025.
Company profile
The company develops, manufactures and sells prescription drugs focused on the central nervous system, including treatments for stroke, Parkinson's disease, schizophrenia and depression, and also sells over-the-counter products such as a gum-care brand and a constipation remedy. It handles production from raw material synthesis through finished drug manufacturing, supplies pharmaceutical products primarily in South Korea, and has formed partnerships with global pharmaceutical companies to pursue markets in the United States, Europe, China and Japan.
Written by AI from the company's latest annual report.
- Korean name
- 명인제약
- Sector
- Biotech & Pharma
- Themes
- Pharmaceuticals
- CEO
- 이관순,차봉권
- Founded
- Nov 1988
- Listed
- Oct 2025
- Listed shares
- 14,600,000
- Fiscal year ends
- Month 12
- Website
- www.myunginph.co.kr
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
Recent filings
See all- Half-year report (Jun 2026)Aug 13, 2026
- Amended: Cash dividend decisionAug 6, 2026
- Preliminary earningsJul 31, 2026
- Cash dividend decisionJul 28, 2026
- Shareholder Register Closure for Cash/Stock Dividend (Record Date) DecisionJul 28, 2026
Titles in Korean until English translations are added.
Also known as: Myungin Pharm / 명인제약 / 317450 / KRX:317450
Source: KRX statistical information